Archivio delibere
Seduta del 28/04/2017
Delibera del 28 Aprile, n. 234 [file.pdf]
Autorizzazione alla Sperimentazione dal titolo: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptorpositive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease”- Protocollo CLEE011A2404
Autorizzazione alla Sperimentazione dal titolo: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptorpositive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease”- Protocollo CLEE011A2404
Data seduta:28/04/2017
In pubblicazione dal: 28/04/2017-al: 13/05/2017
In pubblicazione dal: 28/04/2017-al: 13/05/2017